α 1-antitrypsin increases interleukin-1 receptor antagonist production during pancreatic islet graft transplantation

Cellular and Molecular Immunology

Volumn 11, Issue 4, 2014, Pages 377-386

  Abecassis, Avishag ^a   Schuster, Ronen ^a   Shahaf, Galit ^a   Ozeri, Eyal ^a   Green, Ross ^a   Ochayon, David E ^a   Rider, Peleg ^a   Lewis, Eli C ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

adaptive immunity; inflammation; innate immunity; macrophages; tolerance

Indexed keywords

ALPHA 1 ANTITRYPSIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SYNAPTOTAGMIN I; INTERLEUKIN 1BETA; RELA PROTEIN, MOUSE; SERPINA1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR RELA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HOST CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MACROPHAGE FUNCTION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ACTIVE TRANSPORT; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; GENETICS; GRAFT REJECTION; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; PHOSPHORYLATION; POSTOPERATIVE COMPLICATIONS; UPREGULATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ALPHA 1-ANTITRYPSIN; ANIMALS; CELLS, CULTURED; GRAFT REJECTION; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; ISLETS OF LANGERHANS TRANSPLANTATION; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHORYLATION; POSTOPERATIVE COMPLICATIONS; TRANSCRIPTION FACTOR RELA; UP-REGULATION;

EID: 84905047377     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2014.17     Document Type: Article

References (61)

1. Eizirik DL, Mandrup-Poulsen T. A choice of death-The signaltransduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44: 2115-2133
2. van Der Windt DJ, Bottino R, Casu A, Campanile N, Cooper DK. Rapid loss of intraportal ly transplanted islets: An overview of pathophysiology and preventive strategies. Xenotransplantation 2007; 14: 288-297
3. Mandrup-Poulsen T, Bendtzen K, Nerup J, Dinarello CA, Svenson M, Nielsen JH. Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia 1986; 29: 63-67
4. van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: Etiology, immunology, and therapeutic strategies. Physiol Rev 2011; 91: 79-118
5. Filippi CM, von Herrath MG. Islet beta-cell death-fuel to sustain autoimmunity?. Immunity 2007; 27: 183-185
6. Yamada K, Takane-Gyotoku N, Yuan X, Ichikawa F, Inada C, Nonaka K. Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetologia 1996; 39: 1306-1312
7. Suarez-Pinzon WL, Power RF, Rabinovitch A. Fas ligand-mediated mechanisms are involved in autoimmune destruction of islet beta cells in non-obese diabetic mice. Diabetologia 2000; 43: 1149-1156
8. Ylipaasto P, Smura T, Gopalacharyulu P, Paananen A, Seppanen-Laakso T, Kaijalainen S et al. Enterovirus-induced gene expression profile is critical for human pancreatic islet destruction. Diabetologia 2012; 55: 3273-3283
9. Ramesh A, Chhabra P, Brayman KL. Pancreatic islet transplantation in type 1 diabetes mellitus: An update on recent developments. Curr Diabetes Rev 2013; 9: 294-311
10. Barshes NR, Wyllie S, Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: Implications for intrahepatic grafts. J Leukoc Biol 2005; 77: 587-597
11. Schwarznau A, Hanson MS, Sperger JM, Schram BR, Danobeitia JS, Greenwood KK et al. IL-1beta receptor blockade protects islets against pro-inflammatory cytokine induced necrosis and apoptosis. J Cell Physiol 2009; 220: 341-347
12. Barshes NR, Wyllie S, Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: Implications for intrahepatic grafts. J Leukoc Biol 2005; 77: 587-597
13. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117: 3720-3732
14. Arend WP. The balance between IL-1 and IL-1Ra in Disease. Cytokine Growth Factor Rev 2002; 13: 323-340
15. Akash MS, Rehman K, Sun H, Chen S. Sustained delivery of IL-1Ra from PF127-gel reduces hyperglycemia in Diabetic GK-rats. PloS ONE 2013; 8: E55925
16. Schwarznau A, Hanson MS, Sperger JM, Schram BR, Danobeitia JS, Greenwood KK et al. IL-1beta receptor blockade protects islets against pro-inflammatory cytokine induced necrosis and apoptosis. J Cell Physiol 2009; 220: 341-347
17. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009; 32: 1663-1668
18. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, SeifertB et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526
19. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: Role in biology. Annu Rev Immunol 1998; 16: 27-55
20. Glas R, Sauter NS, Schulthess FT, Shu L, Oberholzer J, Maedler K. Purinergic P2X7 receptors regulate secretion of interleukin-1 receptor antagonist and beta cell function and survival. Diabetologia 2009; 52: 1579-1588
21. Maedler K, Sergeev P, Ehses JA, Mathe Z, Bosco D, Berney T et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci USA 2004; 101: 8138-8143
22. Smith MF, Jr., Eidlen D, Brewer MT, Eisenberg SP, Arend WP, Gutierrez-Hartmann A. Human IL-1 receptor antagonist promoter. Cell type-specific activity and identification of regulatory regions. J Immunol 1992; 149: 2000-2007
23. Andersson J, Bjork L, Dinarello CA, Towbin H, Andersson U. Lipopolysaccharide induces human interleukin-1 receptor antagonist and interleukin-1 production in the same cell. Eur J Immunol 1992; 22: 2617-2623
24. Jenkins JK, Arend WP. Interleukin 1 receptor antagonist production in human monocytes is induced by IL-1 alpha, IL-3, IL-4 and GM-CSF. Cytokine 1993; 5: 407-415
25. Luhm J, Langenkamp U, Hensel J, Frohn C, Brand JM, Hennig H et al. Beta-(1R3)-D-glucan modulates DNA binding of nuclear factors kappaB, AT and IL-6 leading to an anti-inflammatory shift of the IL-1beta/IL-1 receptor antagonist ratio. BMC Immunol 2006; 7: 5
26. Ishida Y, Kondo T, Kimura A, Matsushima K, Mukaida N. Absence of IL-1 receptor antagonist impaired wound healing along with aberrant NF-kappaB activation and a reciprocal suppression of TGF-beta signal pathway. J Immunol 2006; 176: 5598-5606
27. Smith MF Jr, Eidlen D, Arend WP, Gutierrez-Hartmann A. LPSinduced expression of the human IL-1 receptor antagonist gene is controlled by multiple interacting promoter elements. J Immunol 1994; 153: 3584-3593
28. Lewis EC. Expanding the clinical indications for alpha1-Antitrypsin therapy. Mol Med 2012; 18: 957-970
29. Russi EW. Alpha-1 antitrypsin: Now available, but do we need it?. Swiss Med Wkly 2008; 138: 191-196
30. Toso C, Serre-Beinier V, Emamaullee J, Merani S, Armanet M, Wojtusciszyn A et al. The role of macrophage migration inhibitory factor in mouse islet transplantation. Transplantation 2008; 86: 1361-1369
31. Pott GB, Chan ED, Dinarello CA, Shapiro L. Alpha-1-Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol 2009; 85: 886-895
32. Ozeri E, Mizrahi M, Shahaf G, Lewis EC. alpha-1 antitrypsin promotes semimature, IL-10-producing and readily migrating tolerogenic dendritic cells. J Immunol 2012; 189: 146-153
33. Tawara I, Sun Y, Lewis EC, Toubai T, Evers R, Nieves E et al. Alpha-1-Antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 2012; 109: 564-569
34. Shahaf G, Moser H, Ozeri E, Mizrahi M, Abecassis A, Lewis EC. alpha-1-Antitrypsin gene delivery reduces inflammation, increases Tregulatory cell population size and prevents islet allograft rejection. Mol Med 2011; 17: 1000-1011
35. Subramanian S, Shahaf G, Ozeri E, Miller LM, Vandenbark AA, Lewis EC et al. Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD41FoxP31 Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice. Metab Brain Dis 2011; 26: 107-113
36. Toldo S, Seropian IM, Mezzaroma E, Van Tassell BW, Salloum FN, Lewis EC et al. Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. J Mol Cell Cardiol 2011; 51: 244-251
37. Wang Y, He Y, Abraham B, Rouhani FN, Brantly ML, Scott DE et al. Cytosolic, autocrine alpha-1 proteinase inhibitor (A1PI) inhibits caspase-1 and blocks IL-1beta dependent cytokine release in monocytes. PloS ONE 2012; 7: E51078
38. Stoller JK, Aboussouan LS. A review of alpha1-Antitrypsin Deficiency. Am J Respir Crit Care Med 2012; 185: 246-259
39. Kalis M, Kumar R, Janciauskiene S, Salehi A, Cilio CM. alpha 1-Antitrypsin enhances insulin secretion and prevents cytokinemediated apoptosis in pancreatic beta-cells. Islets 2010; 2: 185-189
40. Zhang B, Lu Y, Campbell-Thompson M, Spencer T, Wasserfall C, Atkinson M et al. Alpha1-Antitrypsin protects beta-cells from apoptosis. Diabetes 2007; 56: 1316-1323
41. Zhou X, Shapiro L, Fellingham G, Willardson BM, Burton GF. HIV replication in CD41 T lymphocytes in the presence and absence of follicular dendritic cells: Inhibition of replication mediated by alpha-1-Antitrypsin through altered IkappaBalpha ubiquitination. J Immunol 2011; 186: 3148-3155
42. Chan ED, Pott GB, Silkoff PE, Ralston AH, Bryan CL, Shapiro L. Alpha-1-Antitrypsin inhibits nitric oxide production. J Leukoc Biol 2012; 92: 1251-1260
43. Churg A, Dai J, Zay K, Karsan A, Hendricks R, Yee C et al. Alpha-1-Antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab Invest 2001; 81: 1119-1131
44. Tilg H, Vannier E, Vachino G, Dinarello CA, Mier JW. Antiinflammatory properties of hepatic acute phase proteins: Preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J Exp Med 1993; 178: 1629-1636
45. Lewis EC, Mizrahi M, Toledano M, Defelice N, Wright JL, Churg A et al. alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc Natl Acad Sci USA 2008; 105: 16236-16241
46. Mendez J, Stillman B. Chromatin association of human origin recognition complex, cdc6, and minichromosome maintenance proteins during the cell cycle: Assembly of prereplication complexes in late mitosis. Mol Cell Biol 2000; 20: 8602-8612
47. Pott GB, Chan ED, Dinarello CA, Shapiro L. Alpha-1-Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol 2009; 85: 886-895
48. Tawara I, Sun Y, Lewis EC, Toubai T, Evers R, Nieves E et al. Alpha-1-Antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 2012; 109: 564-569
49. Kline JN, Fisher PA, Monick MM, Hunninghake GW. Regulation of interleukin-1 receptor antagonist by Th1 and Th2 cytokines. Am J Physiol 1995; 269: L92-L98
50. Marie C, Pitton C, Fitting C, Cavaillon JM. IL-10 and IL-4 synergize with TNF-Alpha to induce IL-1ra production by human neutrophils. Cytokine 1996; 8: 147-151
51. Jenkins JK, Malyak M, Arend WP. The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils. Lymphokine Cytokine Res 1994; 13: 47-54
52. Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S. Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med 1994; 179: 1695-1699
53. Tamassia N, Castellucci M, Rossato M, Gasperini S, Bosisio D, Giacomelli M et al. Uncovering an IL-10-dependent NF-kappaB recruitment to the IL-1ra promoter that is impaired in STAT3 functionally defective patients. FASEB J 2010; 24: 1365-1375
54. Subramanian S, Shahaf G, Ozeri E, Miller LM, Vandenbark AA, Lewis EC et al. Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD41FoxP31 Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice. Metab Brain Dis 2011; 26: 107-113
55. Ozeri E, Mizrahi M, Shahaf G, Lewis EC. Alpha-1 antitrypsin promotes semi-mature, interleukin-10-producing and readily migrating tolerogenic dendritic cells. J Immunol 2012; 189: 146-153
56. Koulmanda M, Bhasin M, Hoffman L, Fan Z, Qipo A, Shi H et al. Curative and beta cell regenerative effects of alpha1-Antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci USA 2008; 105: 16242-16247
57. Goldstein S, Reddy P. Tolerance without toxicity?. alpha1-Antitrypsin as a novel alternative to immunosuppression. Expert Rev Clin Immunol 2012; 8: 397-399
58. Thoms HC, Loveridge CJ, Simpson J, Clipson A, Reinhardt K, Dunlop MG et al. Nucleolar targeting of RelAp65 is regulated by COMMD1-dependent ubiquitination. Cancer Res 2010; 70: 139-149
59. Makowiec F, Koveker G, Weber P, Jenss H, Starlinger M. Crohn's disease: Disease activity and recurrence following surgery. Deut Med Wochenschr 1990; 115: 1659-1664. German
60. Hochrainer K, Racchumi G, Zhang S, Iadecola C, Anrather J. Monoubiquitination of nuclear RelA negatively regulates NFkappaB activity independent of proteasomal degradation. Cell Mol Life Sci 2012; 69: 2057-2073
61. Nita IM, Serapinas D, Janciauskiene SM. alpha1-Antitrypsin regulates CD14 expression and soluble CD14 levels in human monocytes in vitro. Int J Biochem Cell Biol 2007; 39: 1165-1176